NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme central to the research on cellular energy metabolism, sirtuin signaling, and DNA repair. It appears in peptide-research catalogs because it is studied in the same mitochondrial-and-aging frameworks as peptides such as MOTS-c — but NAD+ is not a peptide: it is a dinucleotide coenzyme found in every living cell.

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

What Is NAD+?

NAD+ is a molecule of 663 daltons composed of two nucleotides (adenine and nicotinamide) joined through phosphate groups. Its defining role is as an electron carrier in metabolism: it cycles between the oxidized form (NAD+) and the reduced form (NADH) as enzymes transfer electrons during glycolysis, the citric-acid cycle, and oxidative phosphorylation — the core machinery of cellular energy production.

Beyond energy metabolism, NAD+ serves as a substrate for enzyme families whose activity declines with age as cellular NAD+ levels fall:

• Sirtuins (SIRT1–SIRT7) — NAD+-dependent deacetylases involved in DNA repair, mitochondrial biogenesis, inflammation regulation, and stress resistance
• PARPs (poly-ADP-ribose polymerases) — enzymes that consume NAD+ during DNA-damage repair
• CD38 and related NADases — enzymes whose NAD+ consumption increases with age, implicated in the age-related decline of NAD+ levels

Research has investigated NAD+ for its relationship with mitochondrial function, the sirtuin pathway, longevity and aging biology, PARP-mediated DNA repair, and the enzyme CD38’s role in NAD+ decline.

How Does NAD+ Work?

Researchers have investigated its relationship with:

• NAD+ as an energy-metabolism cofactor — the fundamental electron-carrier role: NAD+/NADH cycling drives ATP production in mitochondria, and declining NAD+ is associated with reduced metabolic efficiency in aging tissues
• Sirtuin activation — sirtuins require NAD+ to function; researchers have studied how NAD+ availability gates sirtuin-mediated deacetylation of proteins involved in DNA repair and mitochondrial biogenesis
• DNA-repair (PARP) support — PARP enzymes consume NAD+ while repairing DNA damage; the competition for NAD+ between PARPs and sirtuins is a researched axis of the aging literature
• CD38-driven NAD+ decline — researchers have reported that the enzyme CD38, which degrades NAD+, increases with age and inflammation, contributing to the measured decline in tissue NAD+ levels in older organisms
• Nuclear–mitochondrial communication — declining NAD+ has been studied as a disruptor of signaling between the nucleus and mitochondria, with repletion reported to restore cross-organelle communication in animal models

Key Takeaway: NAD+ is particularly interesting to researchers because it sits at the intersection of metabolism, epigenetics, and aging — a single cofactor whose decline is linked to sirtuin dysfunction, impaired DNA repair, and mitochondrial failure — though the translation from animal findings to human outcomes remains incomplete.

Potential Benefits of NAD+

Mitochondrial & Longevity Research

The landmark longevity papers defined the field. Researchers reported that NAD+ repletion improved mitochondrial function, enhanced muscle function, and extended lifespan in mice — findings reported in Cell (2013), where declining NAD+ was described as inducing a “pseudohypoxic state” disrupting nuclear–mitochondrial communication during aging, and in Science (2016), where NAD+ repletion in aged mice was reported to improve mitochondrial and stem-cell function and enhance lifespan.

A separate line of research examined the NAD+/sirtuin pathway’s modulation of longevity through mitochondrial unfolded-protein-response and FOXO signaling (Cell, 2013), connecting NAD+ biology to conserved longevity pathways.

DNA Repair & PARP Biology

PARP enzymes consume NAD+ while repairing DNA damage — and researchers have investigated how DNA damage, by depleting NAD+, may in turn impair sirtuin function, creating a feedback loop in which genomic instability accelerates metabolic decline. This NAD+–PARP–sirtuin axis is one of the most discussed mechanisms in the aging literature.

CD38 & NAD+ Decline Research

A significant finding of the 2010s was the identification of CD38 as a driver of age-related NAD+ decline: researchers reported that CD38 expression increases with age and inflammation, and that CD38-deficient mice maintain higher NAD+ levels with improved metabolic phenotypes — framing NAD+ decline as partly a consumption problem rather than purely a production problem.

It is important to distinguish these laboratory findings from demonstrated outcomes: the strongest results are in mice, and human NAD+ trials remain limited and short-term.

NAD+ vs. Other Peptides

MOTS-c is NAD+’s closest research neighbor: a mitochondrial-derived peptide studied for AMPK signaling and metabolic homeostasis in obese and diabetic mice. Both are researched within mitochondrial-and-aging frameworks, but MOTS-c is a genuine peptide (16 amino acids) with an endogenous signaling role, while NAD+ is a metabolic cofactor whose evidence base describes a molecule rather than a peptide compound.

NAD+ differs from every true peptide on this site — BPC-157, Semax, Selank, and the rest — in that its literature studies an endogenous metabolic system (NAD+ salvage, sirtuins, PARPs) rather than the administration of a specific peptide compound.

Regulatory Status

NAD+’s regulatory position is worth stating plainly:

• NAD+ is not FDA approved as a drug for any indication. It is an endogenous molecule, not a pharmaceutical product.
• Research-use NAD+ material sold by Vonox Labs is not a medicine, regardless of the volume of the scientific literature on NAD+ biology.
• The animal findings on lifespan and mitochondrial function describe effects in mice under controlled conditions — they do not constitute evidence for any human use.

What Does the Research Say?

The NAD+ literature is large, and its limits should be stated plainly:

First, the landmark findings — lifespan extension, mitochondrial rescue, stem-cell improvement — are in mice. Human trials of NAD+ precursors are small, short, and focused on biomarkers rather than clinical outcomes.

Second, the literature studies NAD+ biology — salvage pathways, sirtuin signaling, CD38 consumption — not the administration of NAD+ material as a compound. Citing longevity findings as evidence for a product is a category error.

Third, NAD+ is not a peptide. Its presence in peptide-research contexts is a discourse convenience, and honest writing should say so plainly — which this guide does.

A mountain of mechanistic literature, a genuine aging-biology rationale, and a translation gap between mice and people: that is the complete honest summary.

Frequently Asked Questions

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme found in every living cell, central to energy metabolism (as an electron carrier in ATP production) and to the activity of enzyme families including sirtuins, PARPs, and CD38. It is not a peptide.

What does the research show?

Landmark mouse studies reported that declining NAD+ disrupts nuclear–mitochondrial communication during aging and that NAD+ repletion improves mitochondrial and stem-cell function and extends lifespan. Research has also identified CD38 as a driver of age-related NAD+ decline and characterized the NAD+–PARP–sirtuin axis in DNA repair and aging biology.

Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme (~663 Da) — two nucleotides joined through phosphates. It is included in peptide-research contexts because it is studied in the same mitochondrial-and-aging frameworks as peptides like MOTS-c, not because it is one.

Is NAD+ FDA approved?

No. NAD+ is an endogenous molecule, not a pharmaceutical product, and it is not FDA approved as a drug for any indication. Research-use NAD+ material is not a medicine.

Has NAD+ been tested in humans?

Small, short-term human trials of NAD+ precursors (such as NMN and nicotinamide riboside) have been conducted, focused on safety and biomarkers rather than clinical outcomes. The landmark longevity and mitochondrial findings are in mice.

The Bottom Line

NAD+ is the most mechanistically studied molecule in the aging-metabolism literature that appears in peptide-research contexts — a redox coenzyme whose decline is linked to sirtuin dysfunction, impaired DNA repair, and mitochondrial failure, with landmark mouse studies reporting lifespan and mitochondrial benefits from repletion.

But it is not a peptide, the literature describes endogenous biology rather than administered-product effects, and the human evidence is thin. For researchers interested in the metabolic core of aging biology, NAD+ remains essential reading — read as biochemistry, not as a compound dossier.

Explore NAD+

Learn more about NAD+ and explore our research-focused NAD+ at Vonox Labs: NAD+

Research. Test. Learn.

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Gomes AP, Price NL, Ling AJY, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. https://pubmed.ncbi.nlm.nih.gov/24360282/ (Landmark study: declining NAD+ disrupts nuclear–mitochondrial signaling in aging mice.)
• Zhang H, Ryu D, Wu Y, et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436-1443. https://pubmed.ncbi.nlm.nih.gov/27127236/ (NAD+ repletion in aged mice: improved mitochondrial/stem-cell function, extended lifespan.)
• Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell. 2013;154(2):430-441. https://pubmed.ncbi.nlm.nih.gov/23870130/ (NAD+/sirtuin pathway in conserved longevity signaling.)
• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. https://pubmed.ncbi.nlm.nih.gov/27304511/ (CD38 identified as a driver of age-related NAD+ decline.)
• Fang EF, Scheibye-Knudsen M, Brace LE, et al. Defective Mitophagy in XPA via PARP-1 Hyperactivation and NAD(+)-SIRT1 Reduced Axis. Science. 2014;344(6182):589-594. https://pubmed.ncbi.nlm.nih.gov/24812403/ (PARP hyperactivation depleting NAD+ and impairing the NAD+–SIRT1 axis.)